Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-fluorouracil + dacarbazine + mitomycin C + vincristine
- Development stage
- Unknown
- Lead developer
- Southern Research
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This combination involves four chemotherapy drugs: **5-fluorouracil** (an antimetabolite that interferes with DNA synthesis), **dacarbazine** (an alkylating agent that damages DNA), **mitomycin C** (an antibiotic that acts as an alkylating agent), and **vincristine** (a vinca alkaloid that inhibits microtubule formation). They are used together to treat various cancers by targeting rapidly dividing cells.
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on 5-fluorouracil + dacarbazine + mitomycin C + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-fluorouracil + dacarbazine + mitomycin C + vincristine.